The Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global market for Pharmaceutical Contract Development And Manufacturing Organization (CMO) has experienced substantial growth in the past years. The market size is projected to increase from $174.33 billion in 2024 to $186.62 billion in 2025, representing a compound annual growth rate (CAGR) of 7.1%.
The Pharmaceutical Contract Development And Manufacturing Organization (CMO) Global Market is predicted to reach a value of $260.83 billion in 2029. The market is expected to grow at a compound annual growth rate (CAGR)
Download Your Free Sample of the 2025 Pharmaceutical Contract Development And Manufacturing Organization (CMO) Market Report and Uncover Key Trends Now!The key drivers in the pharmaceutical contract development and manufacturing organization (cmo) market are:
• Rising government support for the pharmaceutical sector
• Greater accessibility to healthcare services
• Increased investments in the pharmaceutical CMO industry
• Upsurge in biopharmaceutical development activities
The pharmaceutical contract development and manufacturing organization (CMO) market covered in this report is segmented –
1) By Type: Contract Manufacturing Services, Contract Research Services
2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV
2) By End User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small And Medium-Sized Pharmaceutical Companies
The key trends in the pharmaceutical contract development and manufacturing organization (cmo) market are:
• The focus on sustainability is a significant emerging trend in the pharmaceutical CMO market.
• The integration of artificial intelligence and digitalization is increasingly influencing the market.
• There's an emerging trend for innovative products with a focus on resilience in the market.
• Increasing investments and strategic partnerships among market players are shaping the future of the pharmaceutical CMO market.
Major companies in the pharmaceutical contract development and manufacturing organization (cmo) market are:
• Lonza Group
• Catalent Inc
• WuXi AppTec Inc.
• Pfizer Inc
• Recipharm AB
• Almac Group
• Aenova Group
• Baxter International Inc
• SGS Life Science Services SA
• Jubilant Pharmova Ltd
• Dishman Pharmaceuticals
• Kemwell Pvt. Ltd.
• Nipro Corp.
• CMIC Group
• Sawai Pharmaceutical Co., Ltd
• IDT Australia Limited
• Aurigene Pharmaceutical Services Limited
• Vetter Pharma International GMBH
• Consort Medical PLC
• Siegfried Holding AG
• Evonik Industries
• NextPharma
• Royal DSM N.V
• HAUPT Pharma AG
• Boehringer Ingelheim International GmbH
• Famar
• OTC-PharmNEUCA
• Farmacol
• Polska Grupa Farmaceutyczna
• Polpharma
• TZMO
• AbbVie Inc
• Merck & Co Inc
• Amgen Inc
• Gilead Sciences Inc
• Regeneron Pharmaceuticals Inc
• Vertex Pharmaceuticals Inc
• Johnson & Johnson
• Eurofarma Laboratórios S.A.
• Ache Laboratórios Farmacêuticos S.A.
• Blanver Farmoquímica e Farmacêutica S.A.
• Prati-Donaduzzi
• União Química Farmacêutica Nacional S.A
• Laboratorios Richmond S.A.C.I.F.
• Bago S.A.
• Elea Laboratories S.A.C.I. y F.
• Gador S.A.
• LIFEPharma
• Neopharm
• Gulf Pharmaceutical Industries JULPHA
• NewBridge Pharmaceuticals Limited
• Aspen Pharmacare Holdings Limited
• Adcock Ingram Holdings Limited
• Pharma-Q (Pty) Ltd
• Vital Health Foods
• EIPICO (Egyptian International Pharmaceutical Industries Company)
• Pharco Pharmaceuticals
North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2024